Altimmune 2025 Q1 Earnings Improved Net Loss by 19.8%

Altimmune reported its fiscal 2025 Q1 earnings on May 13th, 2025. The total revenue of Altimmune remained stable at $5000 in 2025 Q1 with no significant change from 2024 Q1. Altimmune narrowed losses to $0.26 per share in 2025 Q1 from a loss of $0.34 per share in 2024 Q1 (23.5% improvement). The company reduced its net loss to $-19.57 million in 2025 Q1, improving by 19.8% compared to 2024 Q1. Guidance was in line with expectations, with a focus on upcoming trial results.

Revenue
The revenue for Altimmune remained constant at $5000 for Q1 2025, showing no variation from the same period in the previous year.

Earnings/Net Income
Altimmune posted a net loss of $-19.57 million in Q1 2025, a 19.8% improvement from the $-24.39 million loss in Q1 2024. This reduction in losses equates to $0.26 per share, an improvement over the $0.34 per share loss reported previously, signaling positive progress.

Post-Earnings Price Action Review
The strategy of acquiring Altimmune shares post-revenue drop and holding for 30 days has underperformed the market over the past five years. While the broader S&P 500 delivered annual returns of 19.42%, this approach yielded a negative annualized return of -4.68%. This underperformance suggests the strategy is not in sync with market trends and would not have been a profitable tactic during this timeframe.

CEO Commentary
Vipin Garg, CEO, expressed optimism about the upcoming Phase 2b NASH trial results, underscoring confidence in achieving efficacy and safety targets with pemvidutide. He emphasized the strategic importance of a $100 million credit facility to bolster financial flexibility for ongoing development, marking 2025 as a transformative year for Altimmune.

Guidance
Altimmune is set to announce top-line data from the IMPACT Phase 2b NASH trial in Q2 2025. Preparations for a Phase 3 trial are underway, contingent on successful data outcomes. With $150 million in cash, the company is well-positioned to advance pemvidutide across NASH, AUD, and ALD, extending its cash runway into Q3 2026 with potential additional funding.

Additional News
Recently, Altimmune has secured a $100 million credit facility from Hercules Capital, adding financial strength for ongoing drug development. The company presented promising data at the EASL International Liver Congress, predicting high rates of MASH resolution with pemvidutide. Additionally, Altimmune plans to initiate Phase 2 trials for AUD and ALD in Q2 and Q3 2025, respectively, following FDA clearance of IND applications, marking significant steps in expanding pemvidutide's therapeutic potential.